scholarly journals Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report

2017 ◽  
Vol 11 (1) ◽  
Author(s):  
P. Martin-Romano ◽  
M. Jurado ◽  
M. A. Idoate ◽  
L. Arbea ◽  
J. L. Hernandez-Lizoain ◽  
...  
Keyword(s):  
Case Report ◽  
Complete Remission ◽  
Aromatase Inhibitor ◽  
Performance Status ◽  
Poor Performance ◽  
Inhibitor Therapy ◽  
Poor Performance Status ◽  
Coagulation Disorders ◽  
Uterine Carcinosarcoma ◽  
Aromatase Inhibitor Therapy

scholarly journals Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine

Blood ◽  
1988 ◽  
Vol 72 (4) ◽  
pp. 1333-1339
Author(s):  
RA Larson ◽  
M Wernli ◽  
MM Le Beau ◽  
KM Daly ◽  
LH Pape ◽  
...  
Keyword(s):  
Complete Remission ◽  
Chromosomal Abnormalities ◽  
Bone Marrow Cells ◽  
Performance Status ◽  
Single Agent ◽  
Poor Performance ◽  
High Response Rate ◽  
Poor Performance Status ◽  
High Dose ◽  
High Dose Cytarabine

Seventeen patients with therapy-related myelodysplastic syndrome (t- MDS) or therapy-related acute nonlymphocytic leukemia (t-ANLL) were treated with single-agent high-dose cytarabine (HDAC; 1 to 3 g/m2 every 12 hours for 12 doses). The initial neoplasm was still present in eight patients when t-MDS/t-ANLL developed. Fifteen of the 16 patients with chromosomal abnormalities in bone marrow cells had loss or rearrangement of chromosomes 5 and/or 7. One patient had a t(15;17), and one had inadequate material for cytogenetic analysis. Twelve patients had normal metaphase cells (3% to 71%). Indications for HDAC therapy were progressive pancytopenia in 13 patients or rising blast count in four. Five patients died of marrow hypoplasia following therapy. Four others had refractory t-ANLL and died within the subsequent 5 months. Only one of ten patients with a poor performance status (PS greater than or equal to 2 using the ECOG scale) achieved a complete remission, but all seven patients with a good performance status (PS less than or equal to 1) had a complete remission. Hematologic remissions were achieved in 8 patients (47%) after one (6 patients) or two (2 patients) induction courses and were confirmed by recovery of a 100% normal marrow karyotype in six of the seven patients who were retested. Patients in remission received one to four consolidation courses with HDAC alternating with cytarabine/doxorubicin, but seven relapsed within 8 months (median remission duration, 5 months). In every case, the original chromosomal abnormality reappeared at relapse. HDAC has a high response rate for good-performance patients with t-MDS/t-ANLL, but complete remissions are short even when confirmed cytogenetically and consolidated intensively.

scholarly journals Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission

2013 ◽  
Vol 31 (31) ◽  
pp. 3883-3888 ◽  
Author(s):  
Raya Mawad ◽  
Ted A. Gooley ◽  
Vicky Sandhu ◽  
Jack Lionberger ◽  
Bart Scott ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Complete Remission ◽  
Myeloid Leukemia ◽  
Hematopoietic Cell Transplantation ◽  
Performance Status ◽  
Poor Performance ◽  
Poor Performance Status ◽  
Early Relapse ◽  
First Complete Remission ◽  
Acute Myeloid

Purpose To determine the frequency of allogeneic hematopoietic cell transplantation (HCT) for patients with acute myeloid leukemia (AML) in first complete remission (CR1). Patients and Methods Between January 1, 2008, and March 1, 2011, 212 newly diagnosed patients with AML received treatment at our center. Ninety-five patients age less than 75 years with intermediate- or high-risk AML achieved a complete remission, and 21 patients achieved a morphologic remission with incomplete blood count recovery. Results Seventy-eight (67%; 95% CI, 58% to 76%) of 116 patients received HCT at a median of 2.8 months (range, 0.5 to 19 months) from their CR1 date. The median age was 57 years in both the HCT patient group (range, 18 to 75 years) and the non-HCT patient group (range, 24 to 70 years; P = .514). Between the HCT patients and the non-HCT patients, the mean Eastern Cooperative Oncology Group performance status was 1.1 compared with 1.5, respectively (P = .005), and the average HCT comorbidity score within 60 days of CR1 was 1.7 and 2.1, respectively (P = .68). Twenty-nine (76%) of 38 non-HCT patients were HLA typed, and matched donors were found for 13 of these 29 patients (34% of all non-HCT patients). The most common causes for patients not receiving transplantation in CR1 were early relapse (within 6 months) in 12 patients (32%), poor performance status in eight patients (21%), and physician decision in five patients (13%). Conclusion HCT can be performed in CR1 in the majority of patients with AML for whom it is currently recommended. The main barriers to HCT were early relapse and poor performance status, highlighting the need for improved therapies for patients with AML of all ages.

scholarly journals Dramatic response to alectinib in an ALK ‐positive LCNEC patient with a poor performance status: A case report

2021 ◽  
Vol 9 (9) ◽  
Author(s):  
Kazuki Masuda ◽  
Masafumi Saiki ◽  
So Shimamura ◽  
Shuichiro Ide ◽  
Yoshinori Uchida ◽  
...  
Keyword(s):  
Case Report ◽  
Performance Status ◽  
Poor Performance ◽  
Poor Performance Status ◽  
Alk Positive

scholarly journals Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine

Blood ◽  
1988 ◽  
Vol 72 (4) ◽  
pp. 1333-1339 ◽  
Author(s):  
RA Larson ◽  
M Wernli ◽  
MM Le Beau ◽  
KM Daly ◽  
LH Pape ◽  
...  
Keyword(s):  
Complete Remission ◽  
Chromosomal Abnormalities ◽  
Bone Marrow Cells ◽  
Performance Status ◽  
Single Agent ◽  
Poor Performance ◽  
High Response Rate ◽  
Poor Performance Status ◽  
High Dose ◽  
High Dose Cytarabine

Abstract Seventeen patients with therapy-related myelodysplastic syndrome (t- MDS) or therapy-related acute nonlymphocytic leukemia (t-ANLL) were treated with single-agent high-dose cytarabine (HDAC; 1 to 3 g/m2 every 12 hours for 12 doses). The initial neoplasm was still present in eight patients when t-MDS/t-ANLL developed. Fifteen of the 16 patients with chromosomal abnormalities in bone marrow cells had loss or rearrangement of chromosomes 5 and/or 7. One patient had a t(15;17), and one had inadequate material for cytogenetic analysis. Twelve patients had normal metaphase cells (3% to 71%). Indications for HDAC therapy were progressive pancytopenia in 13 patients or rising blast count in four. Five patients died of marrow hypoplasia following therapy. Four others had refractory t-ANLL and died within the subsequent 5 months. Only one of ten patients with a poor performance status (PS greater than or equal to 2 using the ECOG scale) achieved a complete remission, but all seven patients with a good performance status (PS less than or equal to 1) had a complete remission. Hematologic remissions were achieved in 8 patients (47%) after one (6 patients) or two (2 patients) induction courses and were confirmed by recovery of a 100% normal marrow karyotype in six of the seven patients who were retested. Patients in remission received one to four consolidation courses with HDAC alternating with cytarabine/doxorubicin, but seven relapsed within 8 months (median remission duration, 5 months). In every case, the original chromosomal abnormality reappeared at relapse. HDAC has a high response rate for good-performance patients with t-MDS/t-ANLL, but complete remissions are short even when confirmed cytogenetically and consolidated intensively.

Sign in / Sign up

Export Citation Format

Share Document